204 related articles for article (PubMed ID: 4019576)
1. Initial Canadian experience with artificial blood (Fluosol-DA-20%) in severely anemic patients.
Stefaniszyn HJ; Wynands JE; Salerno TA
J Cardiovasc Surg (Torino); 1985; 26(4):337-42. PubMed ID: 4019576
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic and oxygen transport effects of a perfluorochemical blood substitute, fluosol-DA (20%).
Tremper KK; Lapin R; Levine E; Friedman A; Shoemaker WC
Crit Care Med; 1980 Dec; 8(12):738-41. PubMed ID: 7449405
[TBL] [Abstract][Full Text] [Related]
3. The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA.
Tremper KK; Friedman AE; Levine EM; Lapin R; Camarillo D
N Engl J Med; 1982 Jul; 307(5):277-83. PubMed ID: 7045667
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with Fluosol-DA (20%) in the United States.
Tremper KK; Levine EM; Waxman K
Int Anesthesiol Clin; 1985; 23(1):185-97. PubMed ID: 3884514
[No Abstract] [Full Text] [Related]
5. Perfluorochemical emulsion oxygen transport fluids: a clinical review.
Tremper KK; Anderson ST
Annu Rev Med; 1985; 36():309-13. PubMed ID: 3888055
[TBL] [Abstract][Full Text] [Related]
6. Fluosol DA-20 in the treatment of severe anemia: randomized, controlled study of 46 patients.
Spence RK; McCoy S; Costabile J; Norcross ED; Pello MJ; Alexander JB; Wisdom C; Camishion RC
Crit Care Med; 1990 Nov; 18(11):1227-30. PubMed ID: 1699704
[TBL] [Abstract][Full Text] [Related]
7. Assessment of a 35% fluorocarbon emulsion.
Gould SA; Sehgal LR; Rosen AL; Langdale LA; Sehgal HL; Krause L; Moss GS
J Trauma; 1983 Aug; 23(8):720-4. PubMed ID: 6887290
[TBL] [Abstract][Full Text] [Related]
8. Present status of clinical studies of Fluosol-DA (20%) in Japan.
Mitsuno T; Ohyanagi H
Int Anesthesiol Clin; 1985; 23(1):169-84. PubMed ID: 3980104
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with Fluosol-DA.
Gould SA; Rosen AL; Sehgal LR; Sehgal HL; Moss GS
Prog Clin Biol Res; 1983; 122():331-42. PubMed ID: 6878375
[TBL] [Abstract][Full Text] [Related]
10. Fluosol-DA as a red-cell substitute in acute anemia.
Gould SA; Rosen AL; Sehgal LR; Sehgal HL; Langdale LA; Krause LM; Rice CL; Chamberlin WH; Moss GS
N Engl J Med; 1986 Jun; 314(26):1653-6. PubMed ID: 3713771
[TBL] [Abstract][Full Text] [Related]
11. Perfluorocarbons as blood substitutes: the early years. Experience with Fluosol DA-20% in the 1980s.
Spence RK; Norcross ED; Costabile J; McCoy S; Cernaianu AC; Alexander JB; Pello MJ; Atabek U; Camishion RC
Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(4):955-63. PubMed ID: 7849967
[TBL] [Abstract][Full Text] [Related]
12. Development of a perfluorochemical whole blood substitute (Fluosol-DA, 20%)--an overview of clinical studies with 185 patients.
Suyama T; Yokoyama K; Naito R
Prog Clin Biol Res; 1981; 55():609-28. PubMed ID: 7027272
[TBL] [Abstract][Full Text] [Related]
13. Fluosol DA-20% in treatment of severe anemia: ongoing studies in 52 patients.
Spence RK; McCoy S; Costabile J; Norcross ED; Pello M; Alexander J; Atabek U; Wisdom C; Camishion R
Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):1069. PubMed ID: 1391428
[No Abstract] [Full Text] [Related]
14. Changes of hemodynamics and O2 transport associated with the perfluorochemical blood substitute, Fluosol-DA.
Nishimura N; Sugi T
Crit Care Med; 1984 Jan; 12(1):36-8. PubMed ID: 6690204
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of various colloidal solutions during major abdominal surgery.
Nishimura N; Hiranuma N; Sugi T
Crit Care Med; 1983 Dec; 11(12):940-2. PubMed ID: 6196154
[TBL] [Abstract][Full Text] [Related]
16. Role of Fluosol-DA 20% in prehospital resuscitation.
Elliott LA; Ledgerwood AM; Lucas CE; McCoy LE; McGonigal M; Sullivan MW
Crit Care Med; 1989 Feb; 17(2):166-72. PubMed ID: 2914450
[TBL] [Abstract][Full Text] [Related]
17. A comparison of blood and Fluosol-DA for cardiopulmonary bypass.
Rousou JA; Engelman RM; Anisimowicz L; Dobbs WA
J Cardiovasc Surg (Torino); 1985; 26(5):447-53. PubMed ID: 4030876
[TBL] [Abstract][Full Text] [Related]
18. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis.
Vercellotti GM; Hammerschmidt DE; Craddock PR; Jacob HS
Blood; 1982 Jun; 59(6):1299-1304. PubMed ID: 7082830
[TBL] [Abstract][Full Text] [Related]
19. Surgical use of fluosol-DA in Jehovah's Witness patients.
Ohyanagi H; Nakaya S; Okumura S; Saitoh Y
Artif Organs; 1984 Feb; 8(1):10-8. PubMed ID: 6703920
[TBL] [Abstract][Full Text] [Related]
20. Role of the perfluorocarbon Fluosol-DA in coronary angioplasty.
Kerins DM
Am J Med Sci; 1994 Mar; 307(3):218-21. PubMed ID: 8160713
[No Abstract] [Full Text] [Related]
[Next] [New Search]
